-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is the most common cause of cancer death.
Lung cancer is the most common cause of cancer death.
Evasion of immune destruction is a key mechanism in the development of lung cancer and was described by Hanahan and Weinberg as a new sign of cancer in 2011.
The interaction between programmed cell death receptor 1 (PD-1) on T cells and programmed cell death ligand 1 (PD-L1) on tumor cells plays an important role in immune escape.
The interaction between programmed cell death receptor 1 (PD-1) on T cells and programmed cell death ligand 1 (PD-L1) on tumor cells plays an important role in immune escape.
Recently, experts from the Cancer Translational Research Center in Sydney, Australia conducted a systematic search on MEDLINE and EMBASE papers to understand the effectiveness of anti-PD-1 or anti-PD-L1 monotherapy in the treatment of metastatic NSCLC, the main objective of WiePD-L1 subgroup Response rate (ORR), 1-year and 2-year progression-free survival (PFS), and 2-year and 3-year overall survival (OS) data.
In the end, a total of 9810 patients from 27 studies were included.
In patients who have failed treatment, the benefits of PD-1 blockade over chemotherapy are reflected in the ORR of patients with PD-L1 ≥ 50%, 2-year OS in patients with PD-L1 ≥ 1%, and 1 in unselected patients.
Chemotherapy or PD-1 block ORR in different PD-L1 subgroups.
Chemotherapy or PD-1 block ORR in different PD-L1 subgroups.
If PD-L1≥50%, it shows higher ORR, 2-year PFS and 3-year OS; if PD-L1 is 1%-49%, it shows lower ORR, higher 2-year PFS and Similar 3-year OS; if PD-L1<1%, it shows lower ORR, similar 1-year PFS and lower 2-year OS.
The 1-year and 2-year PFS rates of chemotherapy or PD-1 blockade in different PD-L1 subgroups.
The 1-year and 2-year PFS rates of chemotherapy or PD-1 blockade in different PD-L1 subgroups.
In summary, PD-L1 invalid patients should choose PD-1 blockade therapy and chemotherapy according to their own conditions.
In summary, PD-L1 invalid patients should choose PD-1 blockade therapy and chemotherapy according to their own conditions.
references:
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.
Leave a message here
